What Are Brokerages' Views On Emcure Pharma And Bansal Wire Listings?

Two mega listings hit the D-Street today. Emcure Pharma debuted with a listing price of Rs 1,325.05 on both BSE and NSE, reflecting a 31.25% premium over its issue price of Rs 1,008. The issue size was Rs 1,952 crore. Prathamesh Masdekar, Research Analyst at StoxBox, advised investors to hold the stock for a medium to long-term perspective, a view shared by Prashanth Tapse, Senior VP (Research) at Mehta Equities. Shivani Nyati, Head of Wealth at Swastika Investmart, recommended holding positions with a stop loss at Rs 1,200. Bansal Wire Industries listed at Rs 356 on NSE (up 39%) and Rs 352 on BSE (up 37.5%), with a listing premium of 39% over its issue price of Rs 256. The issue size was Rs 745 crore. Parth Shah, Research Analyst at StoxBox, suggested holding the shares for a medium to long-term perspective. Shivani Nyati echoed this sentiment but advised maintaining a stop loss at Rs 321. In contrast, Prashanth Tapse, Senior VP (Research) at Mehta Equities, recommended booking profits. Listen in to Pawan Nahar detailed report on the IPO listing and what are brokerages views on it.